EA201891514A1 - Комбинированная терапия ингибитором бромодомена и экстратерминального белка - Google Patents

Комбинированная терапия ингибитором бромодомена и экстратерминального белка

Info

Publication number
EA201891514A1
EA201891514A1 EA201891514A EA201891514A EA201891514A1 EA 201891514 A1 EA201891514 A1 EA 201891514A1 EA 201891514 A EA201891514 A EA 201891514A EA 201891514 A EA201891514 A EA 201891514A EA 201891514 A1 EA201891514 A1 EA 201891514A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
bet
extraterminal
protein
combined therapy
Prior art date
Application number
EA201891514A
Other languages
English (en)
Inventor
Зариана Николова
Роберт Чо
Джеффри Алан Стаффорд
Original Assignee
Селджен Квонтисел Рисёрч, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селджен Квонтисел Рисёрч, Инк. filed Critical Селджен Квонтисел Рисёрч, Инк.
Publication of EA201891514A1 publication Critical patent/EA201891514A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

В целом, настоящее изобретение относится к композициям и способам лечения рака, такого как глиобластома и неходжскинская лимфома, или других типов рака, при которых субъект имеет распространенную солидную опухоль, включающим введение ингибитора бромодомена и экстратерминального белка (BET) и по меньшей мере одного химиотерапевтического агента, который не ингибирует BET напрямую. Комбинированная терапия ингибитором BET/химиотерапевтическим агентом может вызывать синергические эффекты, тем самым повышая эффективность лечения рака по сравнению с отдельным введением ингибитора BET или химиотерапевтического агента.
EA201891514A 2015-12-24 2016-12-20 Комбинированная терапия ингибитором бромодомена и экстратерминального белка EA201891514A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387359P 2015-12-24 2015-12-24
US201662413763P 2016-10-27 2016-10-27
PCT/US2016/067860 WO2017112703A1 (en) 2015-12-24 2016-12-20 Bromodomain and extra-terminal protein inhibitor combination therapy

Publications (1)

Publication Number Publication Date
EA201891514A1 true EA201891514A1 (ru) 2019-01-31

Family

ID=59087538

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891514A EA201891514A1 (ru) 2015-12-24 2016-12-20 Комбинированная терапия ингибитором бромодомена и экстратерминального белка

Country Status (16)

Country Link
US (1) US20170182025A1 (ru)
EP (1) EP3393586A4 (ru)
JP (1) JP2019503358A (ru)
KR (1) KR20180095935A (ru)
CN (1) CN108883311A (ru)
AU (1) AU2016379347A1 (ru)
BR (1) BR112018013063A2 (ru)
CA (1) CA3009642A1 (ru)
CL (1) CL2018001724A1 (ru)
EA (1) EA201891514A1 (ru)
IL (1) IL260222A (ru)
MX (1) MX2018007823A (ru)
SG (2) SG11201805385QA (ru)
TW (1) TW201733576A (ru)
WO (1) WO2017112703A1 (ru)
ZA (1) ZA201804223B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3532059T3 (pl) * 2016-10-27 2022-05-09 Celgene Quanticel Research, Inc. Terapia skojarzona z zastosowaniem inhibitora białka bet
US11332466B2 (en) 2017-12-01 2022-05-17 The Board Of Trustees Of The University Of Illinois Pyridinone-based epigenetic modifiers and uses thereof
WO2019204758A1 (en) * 2018-04-20 2019-10-24 Zhiguo Zhang Compositions and methods for treating glioblastoma by modulating a mgmt enhancer
CN109001638B (zh) * 2018-06-22 2020-12-29 格林美（无锡）能源材料有限公司 一种快速评价正极材料包覆前后dcr的方法
KR20210058817A (ko) * 2018-07-23 2021-05-24 셀젠 콴티셀 리서치, 인크. 브로모도메인 억제제의 제조 방법
WO2020169698A1 (en) * 2019-02-21 2020-08-27 F. Hoffmann-La Roche Ag Sensitization of cancer cells to tnf by bet inhibition
EP4025590A4 (en) * 2019-09-03 2024-01-03 Flagship Pioneering Innovations V, Inc. METHODS AND COMPOSITIONS FOR TREATING CANCER
CN111930838B (zh) * 2020-07-23 2023-05-16 金陵科技学院 一种面向时间的分布式档案管理方法
AU2022383951A1 (en) * 2021-11-15 2024-05-16 The Board Of Trustees Of The University Of Illinois Method of treating cancer associated with a ras mutation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089474B2 (en) * 2012-07-13 2015-07-28 Becton Dickinson and Company Ltd. Medical vial access device with pressure equalization and closed drug transfer system and method utilizing same
WO2014080290A2 (en) * 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
KR20150096794A (ko) * 2012-12-21 2015-08-25 제니쓰 에피제네틱스 코포레이션 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
TWI527811B (zh) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
CN109939113B (zh) * 2013-06-21 2022-02-15 恒翼生物医药科技(上海)有限公司 双环溴结构域抑制剂
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
PL3640241T3 (pl) * 2013-10-18 2022-12-05 Celgene Quanticel Research, Inc. Inhibitory bromodomeny
US20150320754A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
BR112018013063A2 (pt) 2018-12-11
SG11201805385QA (en) 2018-07-30
AU2016379347A1 (en) 2018-07-12
MX2018007823A (es) 2018-11-09
US20170182025A1 (en) 2017-06-29
CL2018001724A1 (es) 2018-11-16
WO2017112703A1 (en) 2017-06-29
SG10202013249PA (en) 2021-02-25
EP3393586A4 (en) 2019-07-17
CA3009642A1 (en) 2017-06-29
KR20180095935A (ko) 2018-08-28
TW201733576A (zh) 2017-10-01
IL260222A (en) 2018-07-31
EP3393586A1 (en) 2018-10-31
JP2019503358A (ja) 2019-02-07
ZA201804223B (en) 2019-09-25
CN108883311A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
MX2017007321A (es) Terapias de combinacion.
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
MX2016007351A (es) Terapia de combinacion para tratar cancer.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX369609B (es) Una composición para usarse en el tratamiento de cáncer deficiente en nmt2.
EA201791933A1 (ru) Ингибирование активности olig2
ZA201901367B (en) Inhibition of olig2 activity
EA202090270A1 (ru) Новые замещенные производные ксантина